Insulin resistance and hyperandrogenism are the main features of polycystic ovarian syndrome (PCOS). Low-grade inflammation is also involved in PCOS. This study was performed to evaluate the effect of exenatide on metabolic changes, sexual hormones, inflammatory cytokines, adipokines, and weight changes in a dehydroepiandrosterone (DHEA)-treated rat model. After the model was produced by daily subcutaneous injections of DHEA, rats were given metformin (265 mg/kg), exenatide (10 μg/kg), and saline (1 mL). One group served as a control group. Blood samples and ovarian tissues were removed and prepared for biochemical and hormonal analyses. Exenatide significantly reduced body weight and insulin, testosterone, interleukin 6 (IL-6), PEDF, and visfatin levels. Exenatide also ameliorated changes in ovarian morphology, as evidenced by decreased numbers of cystic follicles and various follicles and elevated numbers of granular cell layers. The effects observed with exenatide were comparable to those observed with metformin. This study has provided evidence that exenatide may be efficient in the treatment of PCOS.
EhrmannDA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236.
2.
LegroRSArslanianSAEhrmannDA. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
3.
RojasJChávezMOlivarL. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050.
4.
HudecovaMHolteJOlovssonMLarssonABerneCPoromaaIS. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome – a long term follow-up. Hum Reprod. 2011;26(6):1462–1468.
5.
GambineriAPattonLAltieriP. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes. 2012;61(9):2369–2374.
6.
GonzálezFRoteNSMiniumJKirwanJP. Increased activation of nuclear factor kB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1508–1512.
7.
RepaciAGambineriAPasqualiR. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30–41.
8.
CarminaEOrioFPalombaS. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006;119(4):356. e1–e6.
9.
OrioFJrPalombaSCascellaT. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(6):2619–2623.
10.
FukuharaAMatsudaMNishizawaM. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–430.
11.
CekmezFCekmezYPirgonO. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22(1):32–37.
12.
PlatiEKouskouniEMalamitsi-PuchnerABoutsikouMKaparosGBakaS. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril. 2010;94(4):1451–1456.
13.
SeowKMHwangJLWangPHHoLTJuanCC. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod. 2011;26(10):2869–2873.
14.
Tombran-TinkJBarnstableCJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci. 2003;4(8):628–636.
15.
YamagishiSAdachiHAbeAElevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(6):2447–2450.
16.
JenkinsAZhangSXGosmanovaA. Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract. 2008;82(1):e5–e7.
17.
YangSLiQZhongL. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab. 2011;96(3):831–836.
18.
AzzizREhrmannDLegroRS. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–1632.
OrioFMangusoFDi BiaseS. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol. 2007;157(1):69–73.
21.
NielsenLLYoungAAParkesDG. Pharmacologyofexenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77–88.
22.
Kim Chung leTHosakaTYoshidaM. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390(3):613–618.
23.
KimSMoonMParkS. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol. 2009;202(3):431–439.
24.
HemmiHEndoTNagasawaK. Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biol Reprod. 2001;64(1):157–162.
25.
WallaceTMLevyJCMatthewsDR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495.
26.
CaldwellASMiddletonLJJimenezM. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology. 2014;155(8):3146–3159.
27.
McNeillyASDuncanWC. Rodent models for human polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373(1-2):2–7.
28.
Artunc-UlkumenBPalaHGPalaEEYavasoqluAYiqtturkGErbasO. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol Endocrinol. 2015;31(3):196–201.
29.
HarborneLRSattarNNormanJEFlemingR. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–4598.
30.
Elkind-HirschKMarrioneauxOBhushanMVernorDBhushanR. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweightwomen with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670–2678.
31.
EhrmannDA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236.
32.
GambineriAPelusiCVicennatiVPagottoUPasqualiR. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–896.
33.
DeUgarteCMBartolucciAAAzzizR. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–1460.
34.
Quintero-CastilloDLuz-AraujoHGuerra-VelázquezM. Lipid profile in obese and non-obese women with polycystic ovary syndrome treated with metformin. Endocrinol Nutr. 2010;57(6):262–267.
35.
Pujante AlarcónPHellín GilMDRománLMFerrer GómezMGarcía ZafraMVTébar MassóJ. Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide. Med Clin (Barc). 2012;139(13):572–578.
36.
SpritzerPMLeckeSBSatlerFMorschDM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149(5):r219–r127.
37.
LiLYangGLiQ. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab. 2008;10(10):921–930.
38.
DerosaGCiceroAFFranzettiIG. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metforminmonotherapy. Can J Physiol Pharmacol. 2013;91(9):724–732.
39.
YangSLvQLuoT. Metformin inhibits expression and secretion of PEDF in adipocyte and hepatocyte via promoting AMPKphosphorylation. Mediators Inflamm. 2013;2013:429207.
